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Apoptosis is a form of programmed cell death that is controlled by aspartate-specific cysteine proteases called caspases. In the immune system, apoptosis counters the proliferation of lymphocytes to achieve a homeostatic balance, which allows potent responses to pathogens but avoids autoimmunity 1, 2 . The CD95 (Fas, Apo-1) receptor triggers lymphocyte apoptosis by recruiting Fas-associated death domain (FADD), caspase-8 and caspase-10 proteins into a death-inducing signalling complex 3, 4 . Heterozygous mutations in CD95, CD95 ligand or caspase-10 underlie most cases of autoimmune lymphoproliferative syndrome (ALPS), a human disorder that is characterized by defective lymphocyte apoptosis, lymphadenopathy, splenomegaly and autoimmunity [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Mutations in caspase-8 have not been described in ALPS, and homozygous caspase-8 deficiency causes embryonic lethality in mice. Here we describe a human kindred with an inherited genetic deficiency of caspase-8. Homozygous individuals manifest defective lymphocyte apoptosis and homeostasis but, unlike individuals affected with ALPS, also have defects in their activation of T lymphocytes, B lymphocytes and natural killer cells, which leads to immunodeficiency. Thus, caspase-8 deficiency in humans is compatible with normal development and shows that caspase-8 has a postnatal role in immune activation of naive lymphocytes.
Some individuals studied at the NIH under approved protocols manifest ALPS-related clinical features but do not have mutations in CD95, CD95 ligand or caspase-10 (ref. 15) . Among them, we identified two siblings in family 66, a 12-yr-old female (patient 1) and an 11-yr-old male (patient 2), who showed lymphadenopathy, splenomegaly and defective CD95-induced apoptosis of peripheral blood lymphocytes (PBLs; Table 1 and Fig. 1a ). Unlike typical individuals affected with ALPS, they had immunodeficiency characterized by recurrent sinopulmonary and herpes simplex virus (HSV) infections and poor responses to immunization (Table 1) . The affected siblings were developmentally normal. The unaffected mother, father and sister were clinically well, although their PBLs showed partial defects in apoptosis mediated by CD95 (Fig. 1a and data not shown). Cells from patient 1 responded normally to the mitochondrial apoptosis inducers staurosporine, ceramide and etoposide (Fig. 1b) .
Biochemical analysis of the death-inducing signalling complex (DISC) showed normal CD95-induced FADD recruitment in all members of family 66 examined (Fig. 1c and data not shown) . By contrast, the cellular abundance of caspase-8 and its recruitment to the DISC were decreased markedly in patient 1 and patient 2, but were normal in the mother (Fig. 1c, d , and data not shown). Neither caspase-8 nor the downstream effector caspase-3 underwent cleavage after Fas ligation, indicating that the DISC from patient 1 cells was not functional (Fig. 1e) . We sequenced the complementary DNAs of CD95, CD95 ligand, caspase-10 and FADD from family members but found no mutations; however, we identified a homozygous C to T mutation in caspase-8 in both patient 1 and patient 2 that changed an arginine to a tryptophan at residue 248 in the p18 protease subunit (Fig. 2a) .
The asymptomatic mother, father and sister were heterozygous carriers of this mutation. We screened 13 extended family members and detected seven asymptomatic heterozygous carriers, but no additional homozygous or immunodeficient individuals. The pedigree revealed consanguinity (Fig. 2b) . We did not find the mutation in DNA samples from 40 normal donors and 40 individuals affected with systemic lupus erythematosus, indicating that the Arg248Trp mutation is not a polymorphism. No additional caspase-8 mutations were found in 10 individuals with common variable immunodeficiency or 30 individuals with ALPS-like conditions (data not shown).
We examined the activity of the mutant enzyme. Using purified chimaeric proteins of wild-type or mutant caspase-8 protease fused to glutathione S-transferase (GST), we found that the mutant protein was unable to cleave the reporter substrate DEVD-AMC (Fig. 2c) . In a cellular reconstitution assay using a caspase-8-deficient Jurkat cell line (I9.2) that fails to undergo apoptosis after CD95 crosslinking, expression constructs encoding wild-type caspase-8 restored CD95-induced apoptosis, but the mutant caspase-8 did not (ref. 16 and Fig. 2d) . In an apoptosis assay in which fusion to the CD8 ectodomain spontaneously drives the multimerization of caspase-8 (ref. 17) , the wild-type construct (CD8-C8wt) induced cell death, whereas the mutant construct (CD8-C8mt) was inactive (Fig. 2e) . Densitometry showed that the abundance of mutant caspase-8 protein in the homozygotes was less than 5% of the wild-type amount, indicating that the mutant protein is unlikely to be partially functional or have allosteric regulatory effects. Thus, the Arg248Trp mutation reduces the stability of the caspase-8 protein and renders it enzymatically inactive.
The association between the homozygous caspase-8 mutation and immunodeficiency led us to study lymphocyte activation responses. We found interleukin-2 (IL-2) production was markedly defective when PBLs from individuals homozygous for the mutant caspase-8 were stimulated through the T-cell receptor (TCR; Fig.  3a) . Notably, the heterozygous family members had a partial defect in IL-2 release. IL-2 production was rescued by stimulation with phorbol myristate acetate (PMA) and ionomycin, which bypass proximal TCR signalling and induce second messengers directly (Fig. 3b) . We also found diminished T-cell proliferation responses to phytohaemagglutinin (PHA) in the two homozygotes, whereas the heterozygotes showed minimal proliferative defects (Fig. 3c ).
CD4-and CD8-postive T-cell populations from patients 1 and 2 showed calcium defects, indicating that the defect in activation affected both subsets of T cells ( Fig. 3d and data not shown).
We examined the influence of caspase-8 on surface activation markers after lymphocyte stimulation ( Table 2 ). The basal surface expression of CD3, CD28 and CD95 was normal (data not shown); however, CD25 induction was markedly defective on both CD4-and CD8-positive T lymphocytes from patients 1 and 2. Induction defects were also observed for CD28, CD71, CD95, CD134, CD152 and MHC class II molecules, whereas induction of CD137 and downregulation of the TCR were not affected (Table 2 and data not shown). Cells from heterozygous family members also showed substantial defects in activation marker expression that were exacerbated by the caspase inhibitor zVAD-fmk (Table 2 and data not shown). By contrast, control experiments showed that lymphocytes from individuals with conventional ALPS and CD95 mutations did not have defective induction of surface activation molecules (data not shown). These results show that caspase-8 has a pivotal role in a proximal signalling event that is essential for a selected subset of TCR-induced responses.
A prominent feature of human homozygous caspase-8 deficiency is severe infection by mucocutaneous HSV. Because defects in natural killer (NK) cells predispose to herpes virus infections, we examined signalling by the CD16 and 2B4 pathways in purified NK cells [18] [19] [20] . Activation of NK cells manifested by CD69 expression was induced by stimulating the cells with antibodies to CD16 or 2B4 in the control samples, but not in samples from patients 1 or 2 (Fig.  3e) . Defective NK cell activation by 2B4 could be reconstituted in normal controls by pretreatment with zVAD-fmk (data not shown). The variable decreases in serum immunoglobulin concentrations in these individuals also prompted us to test their B-cell function. We found that PBLs stimulated with pokeweed mitogen (PWM), a T-cell-dependent mitogen, showed markedly decreased production of immunoglobulin-m (IgM) and immunoglobulin-g (IgG) in patients 1 and 2, whereas the mother showed normal production of immunoglobulins (Fig. 3f) . IgM release was also impaired when purified B cells from patients 1 and 2 were stimulated with the Tcell-independent mitogen Staphylococcus aureus Cowan I (SAC) plus exogenous IL-2 (Fig. 3f) . Thus, immunodeficiency and the resultant opportunistic infections associated with homozygous caspase-8 mutation reflect pleiotropic defects that involve the functions of T, NK and B cells. We validated the association of caspase-8 deficiency with defective lymphocyte activation by two approaches. First, we inactivated caspase-8 in normal human peripheral blood lymphocytes with RNA interference (RNAi) and antisense techniques. Using an electroporation apparatus (Nucleofector System, Amaxa) for efficient gene transfection of resting human PBLs, we introduced two different duplex RNAi ribonucleotides specific for caspase-8 and then stimulated the cells through the TCR complex 21 . Induction of CD69 and CD25 showed that RNAi primer pairs 2 and 3 substantially reduced the response to TCR stimulation as compared with nonspecific primers (Fig. 4a, b) . Controls showed that the specific primer pairs reduced caspase-8 messenger RNA and decreased CD95-induced apoptosis (Fig. 4a, b, insets) . In addition, transfection of caspase-8 antisense constructs impaired CD69 and CD25 induction as compared with vector controls, further showing that interfering with expression of the caspase-8 gene blocks activation responses (Fig. 4c) .
Second, we transfected lymphocytes from patient 1 with an expression construct that encoded either a wild-type fusion protein of caspase-8 and green fluorescent protein (GFP) or GFP alone. Cells transfected with the GFP control did not show upregulation of CD25 expression after stimulation, but cells transfected with the wild-type caspase-8-GFP construct showed a threefold or greater induction of CD25 expression, comparable to normal controls (Fig.  4d, e) . Introduction of a functional caspase-8 molecule by lentiviral gene transduction also rescued the impaired calcium response to TCR stimulation in cells from patient 1 (ref. 22 and Fig. 4f ). We also found that the caspase-8-deficient I9.2 Jurkat line manifested defects in activation responses that could be corrected by retroviral expression of the wild-type caspase-8 gene (Supplementary Information) . Together, these findings show that caspase-8 is necessary for proximal signalling events in lymphocytes.
Our analysis of individuals with inherited caspase-8 deficiency has shown that caspase-8 has a broad role in the activation of T, B and NK cells in addition to its function in conveying signals from death receptors to apoptosis effector mechanisms 12, 13 . Our results also explain how chemical caspase inhibitors interfere with T-cell proliferation [12] [13] [14] . Caspase-8 probably functions in lymphocyte activation independently of CD95, because individuals with type I ALPS and defects in CD95 do not have immunodeficiency, which makes it unlikely that this ligand-receptor pair is involved 23 . The immunodeficiency associated with defective caspase-8 also contrasts with the autoimmune phenotype of individuals with caspase-10 deficiency, despite the structural homology of these two enzymes 11 . Because mice that are deficient in caspase-8 show embryonic lethality, humans that lack caspase-8 function might not be expected to survive. Postnatal survival in humans may be due to the function of caspase-10, the closest paralogue of caspase-8 in humans. Caspase-10 has no known orthologue in mice but may compensate for caspase-8 (refs 3, 4) . The phenotypes associated with caspase-8 and caspase-10 mutations in humans are based on limited genetic data, and studying more individuals with these disorders may define better the different consequences of these mutations. The defects in activation of T, NK and B cells suggest that there may be a common locus of action for caspase-8 in several lymphocyte signalling pathways that will be interesting to uncover. Caspase-8 may be a potentially useful target for a new class of antiinflammatory or immunosuppressive therapeutics and there may be non-apoptotic signalling roles for caspases in cellular responses of non-immune organ systems. Hence, caspase-8 establishes a close link between the biochemical pathways of cellular activation and apoptosis that may shed light on the homeostatic regulation of these seemingly conflicting processes.
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Methods Cellular preparations and analysis
Individuals were studied under NIH-approved ALPS research protocols with informed consent. Wild-type (JA3) and caspase-8-deficient (I9.2) Jurkat cells were gifts from J. Blenis. The 293T cell line was obtained from ATCC. Peripheral blood T lymphocytes were separated on Ficoll gradients and stimulated first with 5 mg ml 21 of PHA (Sigma) for 3 d and then with 100 IU ml 21 IL-2. Apoptosis assays used 10-1,000 ng ml 21 antibodies to CD95 (APO-1.3, Kamiya), 0.1 mg ml 21 staurosporine, 10 mg ml 21 etoposide or 10 mM ceramide as described 5, 24 . We purified B cells using fluorescein isothiocyanate (FITC)-labelled antibodies to CD19, followed by positive selection with anti-FITC Microbeads (MACS). We prepared NK cells by negative selection using the NK Cell Isolation Kit (MACS). Immunoprecipitation and western blot analyses were carried out using antibodies to caspase-3 and FADD (Transduction Laboratories), CD95 (Kamiya) and caspase-8 (a gift from M. Peter).
Sequence analysis, plasmids and mutagenesis
We purified RNA using Trizol (Gibco-BRL) and carried out polymerase chain reaction with reverse transcription (RT-PCR) using the OneStep RT-PCR kit (Qiagen). Sequence analysis was done by dye primer chemistry (Amersham) on an ABI 377 automated sequencer and also by Cleveland Genomics. Bacterially expressed GST fusion proteins, full-length caspase-8 fused to GFP at the carboxy terminus for transfection studies, and CD8-caspase-8 constructs were prepared as described 11, 17 . We generated mutations using the QuickChange Site-Directed Mutagenesis kit (Stratagene).
Biochemical and functional assays
Purification of GST fusion proteins and caspase assays using DEVD-AMC have been described 11 . We transfected I9.2 cells with various constructs and a GFP control vector at a molar ratio of 3:1. After 18 h, cells were treated with antibody to CD95 and assayed for apoptosis. Semiconfluent 293T cells or HeLa cells (RNAi) were transfected using Fugene 6 (Roche) according to the manufacturer's instructions with 2 mg of caspase-8 constructs and 1 mg of a 3LacZ construct. Cells were then fixed and stained for b-galactosidase as described 17 . To transfect resting PBLs, we mixed 5 mg of DNA containing the GFP fusion proteins with 100 ml of the human T-cell Nucleofector solution and then used this to resuspend 5 £ 10 6 PBLs that had been freshly isolated using Ficoll. The PBL suspension was immediately electroporated by a Nucleofector instrument (Amaxa Biosystems). The transfected cells were added to 1 ml of complete RPMI-1640 medium for 24 h before being exposed to plate-bound anti-CD3 and anti-CD28 antibodies (each at 10 mg ml . We generated the antisense construct by inserting the 498-base-pair EcoRI/XmaI caspase-8 cDNA fragment including the translation start site into a pEGFP-C1 vector (Clontech). The expression of CD25 and CD69 was determined by staining the surface of cells with the corresponding phycoerythrin-conjugated antibodies (Pharmingen). We analysed the data after gating on live GFP-positive cells. 514  42  97  18  CD25/CD8  417  23  112  10  CD28  510  178  316  170  CD71  204  30  64  16  CD95  141  39  60  54  CD134  62  22  50  13  CD137  20  17  44  6  CD152  26  12  16  13  MHC class II molecules  120  45  47 
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